Chronic hepatitis B (CHB) poses a major global health burden, with China particularly affected. Effective antiviral therapy ...

Please provide your email address to receive an email when new articles are posted on . The cumulative probability of functional cure was 14.53% at a mean age of 25.75 years. The annual cure rate was ...

New research delves into a traditionally overlooked category of chronic hepatitis B (CHB) patients. While those who are HBeAg-negative with normal ALT levels have been considered low-risk and often ...

HBsAg decline at week 24 and baseline HBsAg levels are better predictors of functional cure than novel virologic markers, while on-treatment HBV RNA and HBeAg levels and dynamic changes are the most ...

The U.S. Food and Drug Administration has given approval to Indianapolis-based Roche Diagnostics to market its Hepatitis B test kit. The test kit, Elecsys HBeAg Immunoassay is a lab test used to ...

Chronic hepatitis B virus (HBV) is the most common cause of liver disease throughout the world. [1] More than 300 million persons are currently estimated to be infected with HBV worldwide. The highest ...

Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B. Histologic ...

Much of the liver injury in HBV infection reflects host immune response rather than a direct cytopathic effect of the virus. During the course of chronic HBV infection, biochemical dysfunction may be ...

Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B. In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis ...

VIENNA -- Tenofovir alafenamide (TAF; Biktarvy) continued to be highly effective for chronic hepatitis B virus (HBV) infection for up to 8 years, according to an analysis of long-term data. Over this ...